256 related articles for article (PubMed ID: 21846853)
21. Radioactive iodine in differentiated thyroid cancer: a national database perspective.
Orosco RK; Hussain T; Noel JE; Chang DC; Dosiou C; Mittra E; Divi V; Orloff LA
Endocr Relat Cancer; 2019 Oct; 26(10):795-802. PubMed ID: 31443087
[TBL] [Abstract][Full Text] [Related]
22. Changes in Population-Level and Institutional-Level Prescribing Habits of Radioiodine Therapy for Papillary Thyroid Cancer.
Jacobs D; Breen CT; Pucar D; Holt EH; Judson BL; Mehra S
Thyroid; 2021 Feb; 31(2):272-279. PubMed ID: 32811347
[No Abstract] [Full Text] [Related]
23. Practice patterns among thyroid cancer surgeons: implications of performing a prophylactic central neck dissection.
Deutschmann MW; Chin-Lenn L; Nakoneshny SC; Dort JC; Pasieka JL; Chandarana SP
J Otolaryngol Head Neck Surg; 2016 Oct; 45(1):55. PubMed ID: 27793192
[TBL] [Abstract][Full Text] [Related]
24. Decreasing Use of Radioactive Iodine for Low-Risk Thyroid Cancer in California, 1999 to 2015.
Park KW; Wu JX; Du L; Leung AM; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2018 Mar; 103(3):1095-1101. PubMed ID: 29267880
[TBL] [Abstract][Full Text] [Related]
25. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
Sacks W; Wong RM; Bresee C; Braunstein GD
Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
[TBL] [Abstract][Full Text] [Related]
26. The 2009 American Thyroid Association guidelines modestly reduced radioactive iodine use for thyroid cancers less than 1 cm.
Roman BR; Feingold JH; Patel SG; Shaha AR; Shah JP; Tuttle RM; Epstein AJ
Thyroid; 2014 Oct; 24(10):1549-50. PubMed ID: 25065817
[No Abstract] [Full Text] [Related]
27. Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group.
Hölzer S; Reiners C; Mann K; Bamberg M; Rothmund M; Dudeck J; Stewart AK; Hundahl SA
Cancer; 2000 Jul; 89(1):192-201. PubMed ID: 10897018
[TBL] [Abstract][Full Text] [Related]
28. Negative remnant
Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
[TBL] [Abstract][Full Text] [Related]
29. Preablation Diagnostic Whole-Body Scan vs Empiric Radioactive Iodine Ablation in Differentiated Thyroid Cancer: Cost-effectiveness Analysis.
Arjani S; Quinn PL; Chokshi RJ
Otolaryngol Head Neck Surg; 2021 Jun; 164(6):1172-1178. PubMed ID: 33076776
[TBL] [Abstract][Full Text] [Related]
30. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.
Sohn SY; Choi JY; Jang HW; Kim HJ; Jin SM; Kim SW; Suh S; Hur KY; Kim JH; Chung JH; Kim SW
Thyroid; 2013 Jun; 23(6):741-7. PubMed ID: 23205883
[TBL] [Abstract][Full Text] [Related]
31. Low-risk thyroid cancer, surgical training, and radioactive iodine.
Shaha AR
Ann Surg Oncol; 2013 Mar; 20(3):703-4. PubMed ID: 23250737
[No Abstract] [Full Text] [Related]
32. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
33. Relapse-free survival after adjuvant radioactive iodine therapy in patients with differentiated thyroid carcinoma with a microscopically positive tumor margin.
Watanabe K; Igarashi T; Uchiyama M; Ojiri H
Ann Nucl Med; 2020 Dec; 34(12):920-925. PubMed ID: 32940889
[TBL] [Abstract][Full Text] [Related]
34. Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence.
Banerjee M; Wiebel JL; Guo C; Gay B; Haymart MR
BMJ; 2016 Jul; 354():i3839. PubMed ID: 27443325
[TBL] [Abstract][Full Text] [Related]
35. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
[TBL] [Abstract][Full Text] [Related]
36. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
[TBL] [Abstract][Full Text] [Related]
37. Thyroid cancer patients' involvement in adjuvant radioactive iodine treatment decision-making and decision regret: an exploratory study.
Sawka AM; Straus S; Gafni A; Meiyappan S; David D; Rodin G; Brierley JD; Tsang RW; Thabane L; Rotstein L; Ezzat S; Goldstein DP
Support Care Cancer; 2012 Mar; 20(3):641-5. PubMed ID: 22072050
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of patients with differentiated thyroid carcinoma following initial therapy.
Jonklaas J; Sarlis NJ; Litofsky D; Ain KB; Bigos ST; Brierley JD; Cooper DS; Haugen BR; Ladenson PW; Magner J; Robbins J; Ross DS; Skarulis M; Maxon HR; Sherman SI
Thyroid; 2006 Dec; 16(12):1229-42. PubMed ID: 17199433
[TBL] [Abstract][Full Text] [Related]
39. Elevated serum thyroglobulin levels at the time of ablative radioactive iodine therapy indicate a worse prognosis in thyroid cancer: an Australian retrospective cohort study.
Matthews TJ; Chua E; Gargya A; Clark J; Gao K; Elliott M
J Laryngol Otol; 2016 Jul; 130 Suppl 4():S50-3. PubMed ID: 27488338
[TBL] [Abstract][Full Text] [Related]
40. High-dose radioactive iodine therapy is associated with decreased risk of recurrence in high-risk papillary thyroid cancer.
Gray KD; Bannani S; Caillard C; Amanat S; Ullmann TM; Romanov P; Brunaud L; Beninato T; Fahey TJ; Mirallie E; Zarnegar R
Surgery; 2019 Jan; 165(1):37-43. PubMed ID: 30274732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
